These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

743 related items for PubMed ID: 18416586

  • 1. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [Abstract] [Full Text] [Related]

  • 2. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC, Tran TT, Poordad FF.
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM.
    World J Gastroenterol; 2014 Apr 28; 20(16):4681-91. PubMed ID: 24782620
    [Abstract] [Full Text] [Related]

  • 4. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May 28; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 5. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.
    World J Gastroenterol; 2013 Feb 21; 19(7):1098-103. PubMed ID: 23467199
    [Abstract] [Full Text] [Related]

  • 6. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB, Atabay A, Akin MS, Yalaki S.
    Eur J Gastroenterol Hepatol; 2013 Sep 21; 25(9):1082-5. PubMed ID: 23524524
    [Abstract] [Full Text] [Related]

  • 7. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.
    Health Technol Assess; 2004 Oct 21; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [Abstract] [Full Text] [Related]

  • 8. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun 21; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul 21; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
    Husa P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Urbanek P.
    Eur J Gastroenterol Hepatol; 2011 May 21; 23(5):375-81. PubMed ID: 21502923
    [Abstract] [Full Text] [Related]

  • 11. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.
    BMC Infect Dis; 2010 Jul 20; 10():212. PubMed ID: 20646277
    [Abstract] [Full Text] [Related]

  • 12. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.
    Lancet; 2014 Aug 02; 384(9941):414-26. PubMed ID: 24907224
    [Abstract] [Full Text] [Related]

  • 13. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H, Laskus T, Kołakowska-Rządzka A, Wasilewski M, Stańczak JJ, Bardadin K, Walewska-Zielecka B, Horban A.
    Adv Med Sci; 2014 Sep 02; 59(2):261-5. PubMed ID: 25117425
    [Abstract] [Full Text] [Related]

  • 14. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.
    Clin Drug Investig; 2008 Sep 02; 28(1):9-16. PubMed ID: 18081356
    [Abstract] [Full Text] [Related]

  • 15. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.
    Liver Int; 2011 Mar 02; 31(3):401-11. PubMed ID: 21281434
    [Abstract] [Full Text] [Related]

  • 16. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.
    New Microbiol; 2005 Jan 02; 28(1):13-21. PubMed ID: 15782622
    [Abstract] [Full Text] [Related]

  • 17. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T.
    Dig Dis Sci; 2005 May 02; 50(5):970-5. PubMed ID: 15906777
    [Abstract] [Full Text] [Related]

  • 18. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K, Sabry A, Shaheen N.
    Int Urol Nephrol; 2011 Sep 02; 43(3):865-73. PubMed ID: 20490669
    [Abstract] [Full Text] [Related]

  • 19. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H, Tatsch F.
    Ann Hepatol; 2012 Sep 02; 11(1):52-61. PubMed ID: 22166561
    [Abstract] [Full Text] [Related]

  • 20. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
    Herrine SK, Brown RS, Bernstein DE, Ondovik MS, Lentz E, Te H.
    Dig Dis Sci; 2005 Apr 02; 50(4):719-26. PubMed ID: 15844708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.